Previous 10 | Next 10 |
home / stock / crpof / crpof news
Ceapro press release ( OTCQX:CRPOF ): Q2 GAAP EPS of $0.02. Revenue of $5.5M (+25.0% Y/Y). For further details see: Ceapro GAAP EPS of $0.02, revenue of $5.5M
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income before tax of $2,177,000 in Q2 2022 vs $676,...
– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the way for Phase 1 clinical trial EDMONTON, Alberta, Aug. 11, 2022 (GLOB...
– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative project with the University of Alberta illustrate how aerogels generated using the PGX Technology can be uniformly loaded w...
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: ...
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...
Ceapro press release (OTCQX:CRPOF): Q1 GAAP EPS of $0.03. Revenue of $6.17M (+31.3% Y/Y). For further details see: Ceapro GAAP EPS of $0.03, revenue of $6.17M
– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit of $2,614,000 in Q1 2022 vs $515,000 in Q1 2021 – Company responds to increased ...
EDMONTON, Alberta, May 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...